Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05144971 · ClinicalTrials.gov registry record

StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation

A clinical trial of ESRD and Diabete Mellitus, sponsored by Nova Biomedical.

Completed
Registry status
175
Enrollment target
1
Study location

NCT05144971 is a study of ESRD and Diabete Mellitus that has completed, run by Nova Biomedical. The registered enrollment target is 175 participants, above the 127-participant average among 13 other ESRD trials with a reported enrollment target (38% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05144971, a study of ESRD and Diabete Mellitus, has completed, sponsored by Nova Biomedical.

COMPLETED
Registry status
175 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study is to assess the performance of the Nova StatStrip A Glucose/Creatinine Meter System in the hands of the subject (lay user) and compare the result to an accepted Glucose/Creatinine reference method in the hands of a trained technician.

Interventions

  • DIAGNOSTIC_TEST Glucose, Creatinine

Study Locations (1)

Florida

  • Excellence Medical Research - Miami Gardens

Trial Details

FieldValue
Enrollment Target 175 participants
Start Date 2021-10-28
Est. Completion 2021-12-03

Sponsor

Nova Biomedical

5 total trials

What the Registry Record Tells You About NCT05144971

The ClinicalTrials.gov registry entry for NCT05144971 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 127-participant average among 13 other ESRD trials with a reported enrollment target (38% higher). The listed sponsor is Nova Biomedical, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with ESRD appearing as the primary indexed condition, and to 1 intervention - of which Glucose, Creatinine is the first listed.

NCT05144971 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT05144971 about?

NCT05144971 is a clinical study titled "StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation". The primary objective of this study is to assess the performance of the Nova StatStrip A Glucose/Creatinine Meter System in the hands of the subject (lay user) and compare the result to an accepted Glucose/Creatinine reference method in the hands of a trained technician.

What is the current status of trial NCT05144971?

This trial is currently completed. The enrollment target is 175 participants. The study started on 2021-10-28. Estimated completion is 2021-12-03.

What conditions does trial NCT05144971 study?

This clinical trial studies the following conditions: ESRD, Diabete Mellitus, CKD.

What interventions are being tested in trial NCT05144971?

The interventions under investigation include: Glucose, Creatinine (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05144971?

This trial is sponsored by Nova Biomedical, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05144971 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ESRD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.